Navigating Pre-Clinical Trials with Laura Kelley & Scaling with Conviction

In this episode of Beyond the Lab, host Stuart Paap sits down with Laura Kelley, co-founder of Aperture Bio, a seed-stage spinout from Mass General Hospital. Laura shares the fascinating origin story of Aperture Bio and details how they are addressing the massive 95% failure rate in oncology drug development.

From navigating difficult pre-clinical terrain to pitching skeptical investors, Laura and Stuart unpack what it truly takes to bring a high-performance imaging platform to market. If you are a founder trying to align your scientific vision with a repeatable business model, this conversation is packed with tactical, real-world advice on driving your venture forward with speed and precision.

Key Takeaways from the Show:

The 95% Failure Problem: Oncology drug candidates face an extraordinarily steep failure rate when transitioning to clinical trials. Aperture Bio uses human tissues and organoids to catch efficacy metrics much earlier in the pipeline, optimizing the path forward.

The Power of Asking "Why?":

Laura details how stepping out of the academic comfort zone allowed them to identify a massive "white space" in pre-clinical development that traditional spatial biology platforms couldn’t efficiently serve.

Building Conviction Under Fire:

Facing skeptical investors is part of the process. Laura reflects on a pivotal pre-seed pitch that taught her to shift the pitch deck's narrative from a place of mere technical detail to deep, undeniable market belief.

The Force Multiplier Effect: In the landscape of biopharma, speed is the ultimate competitive advantage. A successful platform must serve as a "catalyst"—helping partners decide faster, scale accurately, and skip the landmines of drug discovery.

Top Quotes from the Episode:

"Drug discovery is like walking through a field waiting to step on a rake. At any point, you could just get to a 'no-go.' What we’re trying to do is bring those decisions into an iterative, data-driven process." — Laura Kelley

"A company is just a collection of people working on a problem. The effect you're going to have is predicated on the quality and execution of your decisions. You are a catalyst for those higher-quality choices." — Stuart Paap

Connect with Our Guest:

Laura Kelley: Aperture Bio LinkedIn: https://www.linkedin.com/in/lauraekelley/

Connect with us:
Website: dnate.com
Subscribe for expert insights and deep dives into the future of Biotech.